<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00449254</url>
  </required_header>
  <id_info>
    <org_study_id>MAN-OE-US-04</org_study_id>
    <nct_id>NCT00449254</nct_id>
  </id_info>
  <brief_title>Phase 2a Randomized, Double-Blind Study of Oleoyl-Estrone in Male Morbidly Obese Adults</brief_title>
  <official_title>A Phase 2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Safety and Efficacy Study of Oleoyl-Estrone (MP-101) in Male Obese Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manhattan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Manhattan Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, multiple-dose, randomized, double-blind, three-arm, placebo-controlled study of
      fixed-dose repeated oral dosing for 30 days of 10 mg and 30 mg MP-101 and placebo in obese
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the preliminary efficacy</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oleoyl-estrone (MP-101)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is willing and able to provide signed informed consent.

          -  Subject is a male and is between 18-60 years of age.

          -  Subject is obese as defined as a BMI of 40 - 55.

          -  Subject is reasonably healthy and have a reasonably acceptable medical history

          -  Subject has a stable weight for the past 30 days per subject report.

          -  Subject who has at least one factor of the metabolic

          -  Subject exhibits stable behavior patterns with regard to smoking and exercise

          -  Subject can read, speak and write the English language and agrees to follow study
             procedures.

        Exclusion Criteria:

          -  Subjects who have received any investigational medication within 3 months prior to
             administration of study drug

          -  Subjects with confirmed positive results of UDS or Alcohol

          -  Subjects who are unwilling to return to the clinical research center on specified days
             during the treatment periods.

          -  Subjects who have taken exclusionary medication

          -  Subjects with any clinically significant laboratory abnormality or illness which, in
             the opinion of the Investigator, would contraindicate study participation

          -  Subjects who have a history of testing positive for Hepatitis B virus, Hepatitis C
             virus, or HIV.

          -  Subject has been involved in a formal or informal (self-imposed) diet regimen within
             the last 30 days.

          -  Subject has a confirmed diagnosis or history of cancer, with the exception of
             nonmelanoma skin cancer.

          -  Subject is otherwise unsuitable for the study, in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. Luke's-Roosevelt Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2007</study_first_submitted>
  <study_first_submitted_qc>March 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2007</study_first_posted>
  <last_update_submitted>June 4, 2007</last_update_submitted>
  <last_update_submitted_qc>June 4, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2007</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrone</mesh_term>
    <mesh_term>Estropipate</mesh_term>
    <mesh_term>Oleoyl-estrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

